<- Go Home
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Market Cap
GBP 12.7B
Volume
2.7M
Cash and Equivalents
GBP 557.0M
EBITDA
GBP 1.3B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 4.2B
Profit Margin
68.25%
52 Week High
GBP 19.64
52 Week Low
GBP 14.33
Dividend
2.63%
Price / Book Value
2.39
Price / Earnings
20.80
Price / Tangible Book Value
9.74
Enterprise Value
GBP 15.5B
Enterprise Value / EBITDA
10.34
Operating Income
GBP 877.0M
Return on Equity
11.84%
Return on Assets
5.27
Cash and Short Term Investments
GBP 557.0M
Debt
GBP 3.3B
Equity
GBP 5.3B
Revenue
GBP 6.2B
Unlevered FCF
GBP 964.1M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium